Objectives: Remdesivir is currently approved for the treatment of COVID-19. The recommendation for using remdesivir in patients with COVID-19 was based on the in vitro and in vivo activity of this drug against SARS-CoV-2. Methods: This was a prospective observational study conducted on a population of patients hospitalized for COVID-19. The primary endpoint of this study was the impact of remdesivir-containing therapy on 30-day mortality; the secondary endpoint was the impact of remdesivir-containing therapy on the need for high-flow oxygen therapy (HFNC), non-invasive ventilation (NIV), or mechanical ventilation. The data were analyzed after propensity score matching. Results: A total of 407 patients with SARS-CoV-2 pneumonia were consecutively enrolled. Out of these, 294 (72.2%) were treated with remdesivir and 113 (27.8%) were not. Overall, 61 patients (14.9%) were treated during hospitalization with HFNC, NIV, or mechanical ventilation, while 30-day mortality was observed in 21 patients (5.2%). Univariate analysis of patients treated with remdesivir or not showed no differences in 30-day mortality (4% vs. 6%, p = 0.411) in the two study groups. Cox regression analysis, after propensity score matching, showed that therapies, including remdesivir-containing therapy, were not statistically associated with 30-day survival or mortality. The Kaplan–Meier curves of 30-day survival in patients treated with remdesivir or not before ( p = 0.24) and after ( p = 0.88) propensity score matching showed no differences between the two study groups. Finally, patients treated with remdesivir or not showed the same need for HFNC/NIV or mechanical ventilation. Conclusions: This real-life experience of remdesivir use in hospitalized patients with COVID-19 was not associated with significant increases in rates of survival or reduced use of HFNC/NIV or mechanical ventilation compared with patients treated with other therapies not including remdesivir.
【저자키워드】 COVID-19, mechanical ventilation, Pneumonia, Remdesivir, non-invasive ventilation, 【초록키워드】 Treatment, SARS-CoV-2, therapy, Mortality, Hospitalization, prospective observational study, in vitro, survival, Patient, HFNC, in vivo, Therapies, 30-Day mortality, primary endpoint, Analysis, propensity score matching, secondary endpoint, no difference, Cox regression analysis, study groups, high-flow oxygen therapy, Kaplan–Meier, NIV, enrolled, analyzed, approved, conducted, reduced, treated, hospitalized patient, statistically, significant increases in, patients hospitalized, patients treated, patients with COVID-19, patients with SARS-CoV-2, with COVID-19, 【제목키워드】 clinical, Prospective, experience,